+ Watch VICL
on My Watchlist
The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Vical went from close to a one year high last week to a one year low this week after collaborator Sanofi reported negative topline results from the TAMARIS phase III trial of Temusi FGF-1 angiogenesis factor in peripheral vascular disease. The company immediately followed that negative development with a baffling below-market dilutive financing, sending shares tumbling once again. These negative catalysts overshadowed encouraging phase II data for the TransVax CMV vaccine earlier this month.Vical's strongest asset at this time is the phase III trial of Allovectin-7 in melanoma, with topline results expected in mid-2011. I expect the results of this trial to be negative but the nature of baby biotech should cause the share price to increase dramatically in the months leading up to topline results. In addition, Vical has ongoing early phase trials of vaccines for H1N1 and HSV-2. With the cash from the dilutive financing under their belts, the Vical story is far from over.
Time to put my money where my mouth is. 5000 GBMB shares at 1.9 today.
Sold 5000 shares today at 3.64 for a GBMB profit of $8700. This might go up to 7 before Allovectin-7 data in H2 2011, who knows. I'll hold the green thumb as long as possible before the data to take advantage of CAPS skew. I won't regret my sell at this level, since a year ago I would have dumped out at 2.3. No need to replace nervousness with greed.
nice one...I am still on board...greed is good. : )
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions